Zynerba’s cannabidiol gel an Orphan Drug for Fragile X syndrome

The FDA designates Zynerba Pharmaceuticals’ (ZYNE +2%) ZYN002 cannabidiol gel an Orphan Drug for the treatment of Fragile X syndrome, a genetic disorder characterized by learning disabilities and cognitive impairment.

ZYN002 is designed to deliver a controlled dose of cannabidiol transdermally via a permeation-enhanced gel formulation. A Phase 2 study should commence by year end.

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

... read more at: http://seekingalpha.com/news/3140476-zynerbas-cannabidiol-gel-orphan-drug-fragile-x-syndrome